Ranbaxy Laboratories has dipped 3% to Rs 443, in otherwise firm market, on reporting a sharp 90% year-on-year decline in its consolidated net profit at Rs 126 crore for the first quarter ended March 31, 2013 (Q1) due to the base effect. The company had posted a net profit of Rs 1,247 crore in the same period of previous year.
Net sales too, declined 35% to Rs 2,440 crore for the January-March quarter, compared to Rs 3,709 crore in the same period of 2012.
“The profitability for the recently concluded quarter lower when compared to corresponding quarter primarily due to absence of contribution from exclusivities present in the corresponding quarter last year,” Ranbaxy Laboratories said in a statement.
Analyst on an average had expected profit of Rs 144 crore and net sales of Rs 2,637 crore from the pharmaceutical company.
The stock opened at Rs 458 and touched low of Rs 442 on BSE. A combined 2.16 million shares have changed hands on the counter so far on NSE and BSE.
Net sales too, declined 35% to Rs 2,440 crore for the January-March quarter, compared to Rs 3,709 crore in the same period of 2012.
“The profitability for the recently concluded quarter lower when compared to corresponding quarter primarily due to absence of contribution from exclusivities present in the corresponding quarter last year,” Ranbaxy Laboratories said in a statement.
Analyst on an average had expected profit of Rs 144 crore and net sales of Rs 2,637 crore from the pharmaceutical company.
The stock opened at Rs 458 and touched low of Rs 442 on BSE. A combined 2.16 million shares have changed hands on the counter so far on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%